A new anticoagulant with no risk of bleeding
Originally published by Université de Génevé, Medias, on 30 April 2024 A UNIGE team, in collaboration with the University of Sydney, has developed a new type of anticoagulant whose action can be rapidly stopped. The image illustrates the combined action of two molecules cooperating to inhibit thrombin. The antidote dissociates the two molecules, preventing the cooperativity. The association and dissociation of the two molecules is controlled by hybridization of oligonucleotides. © Millicent Dockerill / Nicolas Winssinger Anticoagulant treatments are crucial for managing many conditions, such as heart disease, stroke, and venous thrombosis . Current options, however, carry an i nherent risk of serious bleeding due to trauma or unforeseen events . A team from the University of Geneva (UNIGE) and the University of Sydney has developed a new anticoagulant , designed to have an on-demand reversible activity , with a fast-acting ‘‘antidote’’ . This approach could revolutionize t